Beranda › Limfoma Zona Marginal
Uji klinis Limfoma Zona Marginal yang merekrut di AS
56 studi untuk Limfoma Zona Marginal merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Durham, NC12 studi
- New York City, NY11 studi
- Seattle, WA9 studi
- Milwaukee, WI9 studi
- Boston, MA9 studi
- Baldwin Park, CA9 studi
- Edison, NJ8 studi
- Rochester, MN8 studi
- Columbus, OH8 studi
- Houston, TX8 studi
- Miami, FL7 studi
- Denver, CO7 studi
- Nashville, TN7 studi
- Jacksonville, FL6 studi
- St. Louis, MO6 studi
- Salt Lake City, UT6 studi
- Portland, OR5 studi
- Queens, NY5 studi
- Greenburgh, NY5 studi
- Dallas, TX5 studi
- Chicago, IL5 studi
- Washington, DC5 studi
- Atlanta, GA5 studi
- Cleveland, OH5 studi
- Staten Island, NY4 studi
- Minneapolis, MN4 studi
- New Rochelle, NY4 studi
- Buffalo, NY4 studi
- Los Angeles, CA4 studi
- Tampa, FL4 studi
- Cincinnati, OH4 studi
- Philadelphia, PA4 studi
- Ann Arbor, MI3 studi
- Richmond, VA3 studi
- East Norwalk, CT3 studi
- Providence, RI3 studi
- Mountain View, CA3 studi
- San Francisco, CA3 studi
- Cedar Rapids, IA3 studi
- Scottsdale, AZ3 studi
Berdasarkan negara bagian
- Arizona5 studi
- California18 studi
- Colorado8 studi
- Connecticut4 studi
- Florida15 studi
- Georgia6 studi
- Illinois6 studi
- Iowa4 studi
- Kansas3 studi
- Maryland6 studi
- Massachusetts12 studi
- Michigan5 studi
- Minnesota12 studi
- Missouri6 studi
- New Jersey9 studi
- New York16 studi
- North Carolina14 studi
- Ohio13 studi
- Oregon5 studi
- Pennsylvania5 studi
- Rhode Island3 studi
- Tennessee8 studi
- Texas12 studi
- Utah6 studi
- Virginia4 studi
- Washington10 studi
- Wisconsin10 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07763210A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07231952Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07583810A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Menerima pesertaStudi observasional
Usia 18 hingga 110 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT00923507Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06350318Epco, Zanu, Ritux for R/R FL or MZL
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06563596Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05296070Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07225439A Study of ARC-02 in B-cell NHL
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07691606Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT04792502A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT06149286AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT06340737HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT06792825Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Menerima pesertaFase 1
Usia 18 hingga 81 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT05990465A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06708897A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT07121946Allo HSCT Using RIC and PTCy for Hematological Diseases
Menerima pesertaFase 2
Hingga usia 75 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT05805605A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Jul 2026 · NCT06860880Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06905509Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.